Regulation of cancer cell migration and bone metastasis by RANKL

Nature

Volumn 440, Issue 7084, 2006, Pages 692-696

  Jones, D Holstead ^a,b,i   Nakashima, Tomoki ^a   Sanchez, Otto H ^c,i   Kozieradzki, Ivona ^a,b   Komarova, Svetlana V ^d   Sarosi, Ildiko ^e   Morony, Sean ^e   Rubin, Evelyn ^b   Sarao, Renu ^a   Hojilla, Carlo V ^c   Komnenovic, Vukoslav ^a   Kong, Young Yun ^f   Schreiber, Martin ^g   Dixon, S Jeffrey ^h   Sims, Stephen M ^h   Khokha, Rama ^b,c   Wada, Teiji ^a   Penninger, Josef M ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e AMGEN INC   (United States)

^f Pohang University of Science and Technology (POSTECH)   (South Korea)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h WESTERN UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF ONTARIO INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; BONE; CELLS; DISEASES; ONCOGENIC VIRUSES; TISSUE;

CANCER CELL LINES; CELL MIGRATION; DIFFERENTIATION FACTORS; METASTASIS;

CYTOLOGY;

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; ZOLEDRONIC ACID;

BONE; CANCER; CELLS AND CELL COMPONENTS; DISEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER PAIN; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TUMOR VOLUME;

ANIMALIA;

EID: 33645453481     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04524     Document Type: Article

References (22)

1. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563-572 (2002).
2. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Rev. Cancer 2, 584-593 (2002).
3. Sloan, E. K. & Anderson, R. L. Genes involved in breast cancer metastasis to bone. Cell. Mol. Life Sci. 59, 1491-1502 (2002).
4. Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 1, 571-572 (1889).
5. Moore, M. A. The role of chemoattraction in cancer metastases. Bioessays 23, 674-676 (2001).
6. Muller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
7. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
8. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
9. Arguello, F., Baggs, R. B. & Frantz, C. N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 48, 6876-6881 (1988).
10. Anderson, D. M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
11. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
12. Fata, J. E. et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103, 41-50 (2000).
13. Verschueren, H. et al. Metastatic competence of BW5147 T-lymphoma cell lines is correlated with in vitro invasiveness, motility and F-actin content. J. Leukoc. Biol. 55, 552-556 (1994).
14. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
15. 3 integrins are critical for bone metastasis. Proc Natl Acad. Sci. USA 100, 14205-14210 (2003).
16. 2+ accelerates nuclear translocation of nuclear factor κB in osteoclasts. J. Biol. Chem. 278, 8286-8293 (2003).
17. Sanchez-Sweatman, O. H., Lee, J., Orr, F. W. & Singh, G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur. J. Cancer 33, 918-925 (1997).
18. Peyruchaud, O. et al. Early detection of bone metastases in a murine model of fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J. Bone Miner. Res. 16, 2027-2034 (2001).
19. Guise, T. A. Molecular mechanisms of osteolytic bone metastases. Cancer 88 (Suppl.), 2892-2898 (2000).
20. Zhang, J. et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumour growth in the bone. J. Clin. Invest. 107, 1235-1244 (2001).
21. Morony, S. et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumour burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 61, 4432-4436 (2001).
22. Lelekakis, M. et al. A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17, 163-170 (1999).